Merit Medical Systems (NASDAQ:MMSI) Price Target Raised to $83.00 at Wells Fargo & Company

Merit Medical Systems (NASDAQ:MMSI) had its target price lifted by Wells Fargo & Company from $74.00 to $83.00 in a report released on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical instruments supplier’s stock.

MMSI has been the subject of a number of other reports. Compass Point set a $107.00 price objective on Merit Medical Systems in a report on Monday, April 20th. JPMorgan Chase & Co. cut their target price on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings lowered Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Raymond James Financial reissued an “outperform” rating and issued a $100.00 price target on shares of Merit Medical Systems in a research note on Friday. Finally, Barrington Research lowered their price target on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a report on Monday, April 20th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.30.

Merit Medical Systems Price Performance

NASDAQ MMSI opened at $85.01 on Friday. Merit Medical Systems has a 52 week low of $59.74 and a 52 week high of $94.75. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 35.13, a price-to-earnings-growth ratio of 2.59 and a beta of 0.52. The company has a 50-day moving average price of $69.87 and a two-hundred day moving average price of $71.78.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, beating the consensus estimate of $0.96 by $0.23. The company had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.97%. Merit Medical Systems’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Analysts forecast that Merit Medical Systems will post 3.62 EPS for the current year.

Insider Buying and Selling

In related news, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the transaction, the director owned 7,809 shares in the company, valued at $488,921.49. This trade represents a 39.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian G. Lloyd bought 2,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider owned 2,000 shares of the company’s stock, valued at $125,240. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.70% of the stock is owned by company insiders.

Institutional Trading of Merit Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of MMSI. SG Americas Securities LLC bought a new position in Merit Medical Systems during the fourth quarter valued at about $1,537,000. Bessemer Group Inc. grew its holdings in Merit Medical Systems by 54.2% during the fourth quarter. Bessemer Group Inc. now owns 313,981 shares of the medical instruments supplier’s stock worth $27,674,000 after acquiring an additional 110,392 shares during the period. WINTON GROUP Ltd bought a new stake in Merit Medical Systems in the fourth quarter worth about $12,239,000. Norges Bank acquired a new stake in Merit Medical Systems in the 4th quarter valued at about $75,957,000. Finally, Peak Retirement Planning Inc. lifted its holdings in Merit Medical Systems by 35.4% in the 4th quarter. Peak Retirement Planning Inc. now owns 32,472 shares of the medical instruments supplier’s stock valued at $2,862,000 after acquiring an additional 8,494 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

More Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 results exceeded expectations: Merit reported revenue of $418.8 million, up 9.5% year over year and above the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, beating estimates of $0.96; GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance
• Positive Sentiment: 2026 guidance was raised: Management now expects full-year adjusted EPS of $4.25-$4.35, above the $3.98 analyst consensus. Broad-based product growth, revenue gains and expanding margins supported the improved outlook. MMSI Q2 Earnings, Revenues Beat Estimates; 2026 Guidance Raised
• Positive Sentiment: Analyst targets moved higher: Needham raised its target to $101 and maintained a Buy rating; BTIG lifted its target to $105 and maintained Buy; and JPMorgan raised its target to $95 with an Overweight rating. These revisions indicate increased confidence in Merit’s growth and earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
• Neutral Sentiment: Analyst opinion remains mixed: Wells Fargo raised its target to $83 but retained an Equal Weight rating, leaving its target below the stock’s recent trading level. Wells Fargo Raises Merit Medical Price Target
• Negative Sentiment: Cash generation weakened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million, a potential concern despite the strong earnings performance. Merit Medical Second Quarter Results

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.